The Fall Research Roundup highlights new studies now enrolling people living with FTD, care partners, and biological family members.

Registry data is helping to bridge the gap between the FTD and ALS research communities and to accelerate recruitment for future clinical trials.

Registry data reveal which FTD subtypes and genes have the highest representation of research-ready participants, helping scientists design stronger, more focused studies.

Alector has announced topline results from its Phase 3 INFRONT-3 trial of latozinemab for FTD-GRN.

Life with FTD is about so much more than medical symptoms. To better understand the impact of FTD disorders, our September Quick Question asked …